{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:07:39Z","timestamp":1784030859130,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004091","name":"Kumamoto University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.resinv.2026.101461","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T21:16:22Z","timestamp":1780348582000},"page":"101461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical significance of 18F-FDG uptake in interstitial lung lesions in lung cancer patients with interstitial lung disease treated with immune checkpoint inhibitor therapy"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6432-2872","authenticated-orcid":false,"given":"Tsuguhiro","family":"Furukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7714-1552","authenticated-orcid":false,"given":"Kimitaka","family":"Akaike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Saruwatari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seitaro","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1404-6830","authenticated-orcid":false,"given":"Hiroko","family":"Okabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5950-7821","authenticated-orcid":false,"given":"Shohei","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Iyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9680-7559","authenticated-orcid":false,"given":"Yusuke","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2490-9409","authenticated-orcid":false,"given":"Aiko","family":"Masunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1773-8485","authenticated-orcid":false,"given":"Hidenori","family":"Ichiyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Sakagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2026.101461_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/thoraxjnl-2021-218281","article-title":"Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis","volume":"77","author":"Naoi","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2026.101461_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01484-2024","article-title":"Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study","volume":"65","author":"Yoon","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2026.101461_bib3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1183\/23120541.00184-2019","article-title":"Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan","volume":"6","author":"Minegishi","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.resinv.2026.101461_bib4","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101461_bib5","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101461_bib6","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101461_bib7","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3389\/fonc.2020.01785","article-title":"Pneumonitis induced by immune checkpoint inhibitors: from clinical data to translational investigation","volume":"10","author":"Zhu","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.resinv.2026.101461_bib8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3892\/etm.2024.12670","article-title":"Immune checkpoint inhibitor therapy-related pneumonitis: how, when and why to diagnose and manage","volume":"28","author":"Lavalle","year":"2024","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.resinv.2026.101461_bib9","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.2967\/jnumed.116.174946","article-title":"18F-FDG uptake in less affected lung field provides prognostic stratification in patients with interstitial lung disease","volume":"57","author":"Nobashi","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.resinv.2026.101461_bib10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10147-019-01584-x","article-title":"Predictive value of 18F-FDG PET\/CT for acute exacerbation of interstitial lung disease in patients with lung cancer and interstitial lung disease treated with chemotherapy","volume":"25","author":"Akaike","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101461_bib11","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.21037\/jtd-22-604","article-title":"Clinical impact of SUVmax of interstitial lesions in lung cancer patients with interstitial lung disease who underwent pulmonary resection","volume":"14","author":"Akaike","year":"2022","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.resinv.2026.101461_bib12","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12890-021-01659-4","article-title":"18F-FDG PET\/CT predicts acute exacerbation in idiopathic pulmonary fibrosis after thoracic surgery","volume":"21","author":"Yoon","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2026.101461_bib13","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.21037\/jtd-24-1512","article-title":"The value of fibrosis score and 18F-FDG by positron emission tomography-computed tomography in lung cancer patients with interstitial lung disease","volume":"17","author":"Xu","year":"2025","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.resinv.2026.101461_bib14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41598-024-83787-5","article-title":"Prognostic value of [18F]FDG PET\/CT in patients with idiopathic pulmonary fibrosis","volume":"15","author":"Whi","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.resinv.2026.101461_bib15","first-page":"1135","article-title":"[18F]FDG PET\/CT predicts patient survival in patients with systemic sclerosis-associated interstitial lung disease","volume":"66","author":"Lilburn","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.resinv.2026.101461_bib16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3857\/roj.2011.29.3.181","article-title":"Factors predicting radiation pneumonitis in locally advanced non-small cell lung cancer","volume":"29","author":"Kim","year":"2011","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.resinv.2026.101461_bib17","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.21037\/jtd.2018.11.132","article-title":"Radiation pneumonitis in lung cancer treated with volumetric modulated arc therapy","volume":"10","author":"Wu","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.resinv.2026.101461_bib18","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2026.101461_bib19","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2026.101461_bib20","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.resinv.2026.101461_bib21","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00595-013-0711-5","article-title":"Acute exacerbation of interstitial lung disease with lung cancer after surgery: evaluation with 2-(18)-fluoro-2-deoxy-D-glucose positron emission tomography","volume":"44","author":"Maniwa","year":"2014","journal-title":"Surg Today"},{"key":"10.1016\/j.resinv.2026.101461_bib22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.lungcan.2021.03.014","article-title":"Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease","volume":"155","author":"Tasaka","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2026.101461_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107958","article-title":"Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: a multicenter, open-label prospective trial","volume":"196","author":"Shibaki","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.resinv.2026.101461_bib24","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/1759-7714.12759","article-title":"Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease","volume":"9","author":"Kanai","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.resinv.2026.101461_bib25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2026.101461_bib26","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/cam4.2104","article-title":"Risk of immune-related pneumonitis for PD1\/PD-L1 inhibitors: systematic review and network meta-analysis","volume":"8","author":"Huang","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.resinv.2026.101461_bib27","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.chest.2021.12.656","article-title":"Clinical outcomes of immune checkpoint inhibitor therapy in patients with advanced non-small cell lung cancer and preexisting interstitial lung diseases: a systematic review and meta-analysis","volume":"161","author":"Zhang","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2026.101461_bib28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5415\/apallergy.0000000000000146","article-title":"From tumor to tolerance: a comprehensive review of immune checkpoint inhibitors and immune-related adverse events","volume":"14","author":"Sutanto","year":"2024","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.resinv.2026.101461_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3892\/etm.2024.12775","article-title":"Advances in understanding the role of interleukins in pulmonary fibrosis","volume":"29","author":"He","year":"2024","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.resinv.2026.101461_bib30","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1378\/chest.12-1359","article-title":"Glucose transporter-1 distribution in fibrotic lung disease: association with [18F]-2-fluoro-2-deoxyglucose-PET scan uptake, inflammation, and neovascularization","volume":"143","author":"El-Chemaly","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2026.101461_bib31","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1164\/rccm.201504-0780OC","article-title":"Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis","volume":"192","author":"Xie","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2026.101461_bib32","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1096\/fj.201600428R","article-title":"Profibrotic up-regulation of glucose transporter 1 by TGF-beta involves activation of MEK and mammalian target of rapamycin complex 2 pathways","volume":"30","author":"Andrianifahanana","year":"2016","journal-title":"FASEB J"},{"key":"10.1016\/j.resinv.2026.101461_bib33","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jtho.2020.08.018","article-title":"A phase 2 study of atezolizumab for pretreated NSCLC with idiopathic interstitial pneumonitis","volume":"15","author":"Ikeda","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.resinv.2026.101461_bib34","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.2214\/AJR.07.3177","article-title":"Accuracy of high-resolution CT in the diagnosis of diffuse lung disease: effect of predominance and distribution of findings","volume":"191","author":"Sundaram","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.resinv.2026.101461_bib35","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1148\/radiol.12112516","article-title":"Interobserver variability in the CT assessment of honeycombing in the lungs","volume":"266","author":"Watadani","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.resinv.2026.101461_bib36","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.240016","article-title":"Meta-analysis of interobserver agreement in assessment of interstitial lung disease using high-resolution CT","volume":"313","author":"Delaney","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.resinv.2026.101461_bib37","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/annonc\/mdz077","article-title":"Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib","volume":"30","author":"Schoenfeld","year":"2019","journal-title":"Ann Oncol"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221253452600095X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221253452600095X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:40:48Z","timestamp":1784029248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221253452600095X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S221253452600095X"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101461","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical significance of 18F-FDG uptake in interstitial lung lesions in lung cancer patients with interstitial lung disease treated with immune checkpoint inhibitor therapy","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101461","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.","name":"copyright","label":"Copyright"}],"article-number":"101461"}}